Enovis posted Q2 net sales of $583 million, up 3% year over year on a reported basis, with organic growth of 5%.
GAAP net loss narrowed to $1 million, or $0.02 per share, from a larger loss a year earlier.
Non-GAAP adjusted EBITDA rose to $104 million, lifting margin to 17.9% from 16.2%.
Reconstructive net sales climbed 8% reported, while Prevention & Recovery net sales slipped 1% reported.
Maintained full-year 2026 outlook, including revenue of $2.31 billion-$2.37 billion, adjusted EBITDA of $425 million-$435 million, adjusted EPS of $3.52-$3.73.
ENOV•
